Encephalopathy Connectomic Collapse Atlas (ECCA-TRA) | Traumatic Encephalopathy Biomarker Panel

SCF-ECCA-TRA-BIO-0008

Traumatic Encephalopathy Biomarker Panel

Neurotraumatic Connectomic Collapse Validation System

FDA-Aligned Endpoint Framework for Precision Acupuncture Planning

Encephalopathy Connectomic Collapse Atlas (ECCA-TRA)

I. PURPOSE

The SCF Traumatic Encephalopathy Biomarker Panel is designed to:

Establish traumatic encephalopathy diagnostic support
Quantify neurotraumatic connectomic collapse severity
Identify acute, subacute, and chronic neurotrauma phenotypes
Forecast post-traumatic cognitive, motor, autonomic, and psychiatric outcomes
Stratify precision acupuncture neurocircuit selection
Monitor rehabilitation response
Support FDA-aligned translational endpoint development
Enable personalized neuromodulation planning after traumatic brain injury

II. SCF TRAUMATIC ENCEPHALOPATHY BIOMARKER DOMAINS

Domain	Function
Trauma Severity	Measures acute injury burden
Neuroaxonal Injury	Measures diffuse axonal injury
Glial Activation	Measures astrocytic and microglial response
BBB Integrity	Measures neurovascular disruption
Neuroimmune Activation	Measures secondary inflammatory injury
Mitochondrial Function	Measures ATP-redox collapse
Autonomic Function	Measures brainstem-autonomic instability
Connectomic Function	Measures network synchronization
Cervical–Vestibular Function	Measures cervico-brainstem dysfunction
Sensorimotor Function	Measures motor recovery
Cognitive/Psychiatric Function	Measures executive, memory, and limbic outcomes
Prognostic Forecasting	Predicts recovery trajectory

III. TRAUMA SEVERITY PANEL

Tier 1 Acute Neurotrauma Layer

Biomarker / Endpoint	FDA-Aligned Assay	Normal	Mild Risk	Moderate Risk	Severe Risk
Glasgow Coma Scale	Clinical neurologic exam	15	13–14	9–12	≤8
Post-Traumatic Amnesia	Clinical assessment	None	<24 h	1–7 d	>7 d
Loss of Consciousness	Clinical assessment	None	<30 min	30 min–24 h	>24 h
CT/MRI Structural Injury	CT/MRI	None	Microhemorrhage suspected	Contusion/hemorrhage	Mass effect / diffuse injury
Pupillary Reactivity	Neurologic exam	Normal	Sluggish	Asymmetric	Fixed/dilated

Endpoint

Trauma Severity Index (TSI)

IV. NEUROAXONAL INJURY PANEL

Tier 2 Diffuse Axonal Injury Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
NfL	Simoa / CLIA LDT	<10 pg/mL	10–20	20–50	>50
Total Tau	Simoa / CLIA LDT	<2 pg/mL	2–4	4–8	>8
UCH-L1	FDA-cleared TBI-context assay / CLIA	<100 pg/mL	100–200	200–400	>400
Neurogranin	ELISA / CLIA LDT	Lab reference	Elevated	High	Very High
MBP	Immunoassay	Lab reference	Elevated	High	Very High

Endpoint

Neuroaxonal Injury Index (NAII)

V. GLIAL ACTIVATION PANEL

Tier 3 Neuroglial Response Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
GFAP	FDA-cleared TBI-context assay / Simoa	<120 pg/mL	120–250	250–500	>500
S100B	Immunoassay	<0.1 ng/mL	0.1–0.2	0.2–0.5	>0.5
YKL-40	ELISA / CLIA LDT	<60 ng/mL	60–100	100–150	>150
sTREM2	ELISA / CLIA LDT	Lab reference	Elevated	High	Very High
MCP-1 / CCL2	Multiplex immunoassay	Lab reference	Elevated	High	Very High

Endpoint

Traumatic Glial Activation Score (TGAS)

VI. BBB INTEGRITY PANEL

Tier 4 Neurovascular Disruption Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
S100B	Immunoassay	<0.1 ng/mL	0.1–0.2	0.2–0.5	>0.5
Albumin Quotient	CSF/Serum	<6.5	6.5–8	8–12	>12
MMP-9	ELISA / CLIA LDT	<150 ng/mL	150–250	250–400	>400
Claudin-5 / Occludin fragments	ELISA / research-use	Low	Elevated	High	Very High
vWF Antigen	Coagulation immunoassay	Lab reference	Elevated	High	Very High

Endpoint

Traumatic BBB Disruption Index (T-BBDI)

VII. NEUROIMMUNE ACTIVATION PANEL

Tier 5 Secondary Injury Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
IL-6	Multiplex immunoassay	<2 pg/mL	2–10	10–50	>50
TNF-α	Multiplex immunoassay	<5 pg/mL	5–15	15–30	>30
IL-1β	Multiplex immunoassay	<1 pg/mL	1–5	5–15	>15
HMGB1	ELISA / CLIA LDT	Lab reference	Elevated	High	Very High
hsCRP	Immunoassay	<1 mg/L	1–3	3–10	>10

Endpoint

Traumatic Secondary Injury Amplification Score (T-SIAS)

VIII. MITOCHONDRIAL FAILURE PANEL

Tier 6 Bioenergetic Collapse Layer

Biomarker	Assay	Baseline	Mild	Moderate	Severe
Lactate	Clinical chemistry	0.5–2.0 mmol/L	2–3	3–5	>5
Pyruvate	LC-MS/MS	Lab reference	Elevated	High	Very High
Lactate/Pyruvate Ratio	LC-MS/MS	<20	20–30	30–40	>40
cf-mtDNA	qPCR / research-use	Low	Elevated	High	Very High
ATP Production Rate	Seahorse / research-use	Normal	↓10%	↓25%	↓50%

Endpoint

Traumatic Bioenergetic Failure Index (T-BFI)

IX. AUTONOMIC FUNCTION PANEL

Tier 7 Brainstem-Autonomic Layer

Biomarker / Endpoint	Assay	Baseline	Mild	Moderate	Severe
HRV SDNN	ECG / validated wearable	>100 ms	80–100	50–80	<50
RMSSD	ECG / validated wearable	>30 ms	20–30	10–20	<10
LF/HF Ratio	HRV	1–2	2–3	3–5	>5
Orthostatic HR Rise	Active stand / tilt table	<20 bpm	20–30	30–40	>40
Baroreflex Sensitivity	Autonomic testing	Normal	Mild reduction	Moderate reduction	Severe reduction

Endpoint

Traumatic Autonomic Collapse Index (T-ACI)

X. CONNECTOMIC FUNCTION PANEL

Tier 8 Network Synchronization Layer

Biomarker / Endpoint	Assay	Baseline	Mild	Moderate	Severe
EEG Delta Power	qEEG	Normal	+20%	+50%	+100%
EEG Theta Excess	qEEG	Normal	Mild	Moderate	Severe
Alpha Connectivity	qEEG	Normal	↓10%	↓25%	↓50%
rs-fMRI Connectivity	MRI	Normal	↓10%	↓25%	↓50%
DTI Fractional Anisotropy	MRI-DTI	Normal	↓5%	↓10%	↓20%
Susceptibility Microbleeds	SWI MRI	None	1–2	3–10	>10 / diffuse

Endpoint

Traumatic Connectomic Collapse Index (T-CCI)

XI. CERVICAL–VESTIBULAR FUNCTION PANEL

Tier 9 Cervico-Brainstem Layer

Endpoint	Assay	Normal	Mild	Moderate	Severe
Vestibular/Ocular Motor Screening	VOMS	Negative	Mild symptoms	Moderate symptoms	Severe/prolonged symptoms
Dizziness Handicap Inventory	Questionnaire	0–14	16–34	36–52	>54
Cervical ROM	Goniometry	Normal	↓10%	↓25%	↓50%
Balance Error Scoring System	Clinical test	Normal	Mild errors	Moderate	Severe
Dynamic Visual Acuity	Vestibular test	Normal	Mild deficit	Moderate	Severe

Endpoint

Cervico-Vestibular Instability Score (CVIS)

XII. SENSORIMOTOR FUNCTION PANEL

Tier 10 Motor Recovery Layer

Endpoint	Normal	Mild	Moderate	Severe
NIH Stroke Scale	0	1–4	5–15	>15
Modified Rankin Scale	0	1–2	3–4	5–6
Fugl-Meyer Motor Score	>95	75–95	40–74	<40
Gait Velocity	Normal	Mild reduction	Moderate reduction	Severe reduction
Grip Strength	Age/sex norm	↓10%	↓25%	↓50%

Endpoint

Traumatic Sensorimotor Recovery Index (T-SRI)

XIII. COGNITIVE / PSYCHIATRIC ENDPOINT PANEL

Tier 11 Functional Outcome Layer

Endpoint	Normal	Mild	Moderate	Severe
MoCA	≥26	22–25	16–21	<16
Trail Making Test-B	<75 sec	75–120	120–180	>180
Digit Symbol Substitution	Age norm	↓10%	↓25%	↓50%
Rivermead Post-Concussion Symptoms	0–4	5–20	21–35	>35
PHQ-9	0–4	5–9	10–19	≥20
PCL-5	<31	31–37	38–49	≥50

Endpoint

Traumatic Cognitive–Limbic Performance Score (T-CLPS)

XIV. SCF ACUPUNCTURE RESPONSE FORECAST PANEL

Biomarker Pattern	Predicted Dysfunction	Primary Acupuncture Network
Elevated GFAP + UCH-L1	Acute neurotraumatic injury	GV20 + Sishencong + ST36
Elevated NfL + Tau	Diffuse axonal injury	GV20 + GV24 + GB20
Elevated IL-6 + HMGB1	Secondary neuroinflammatory injury	ST36 + LI11 + LI4
High S100B + MMP-9	BBB disruption	GV20 + PC6 + GB20
HRV suppression	Brainstem-autonomic dysfunction	PC6 + HT7 + CV17
Reduced DTI FA / rs-fMRI connectivity	Connectomic fragmentation	GV20 + GV24 + Sishencong
VOMS positive + cervical ROM loss	Cervico-brainstem instability	GB20 + BL10 + SI3
Motor impairment	Sensorimotor network disruption	GB34 + BL40 + ST36
High PHQ-9/PCL-5	Limbic-trauma dysregulation	HT7 + Yintang + LV3

XV. SCF PRECISION FORECASTING MODEL

Risk Class	Criteria	Predicted Acupuncture Planning Implication
Low-Risk Recovery	GCS 15, GFAP <250, NfL <20, preserved HRV, MoCA >24	Standard connectomic support; monitor symptoms
Intermediate Risk	GCS 9–14 or PTA >24h, GFAP 250–500, moderate qEEG slowing, MoCA 18–24	Extended protocol; combine neurorehab + autonomic stabilization
High-Risk Progression	GCS ≤8, GFAP >500, NfL >50, severe DTI disruption, MoCA <18	Intensive neurocritical / rehab management; acupuncture adjunct only

XVI. COMPOSITE SCF TRAUMATIC ENCEPHALOPATHY SCORE

Domain	Weight
Trauma Severity	15%
Neuroaxonal Injury	15%
Glial Activation	15%
BBB Integrity	10%
Neuroimmune Activation	10%
Mitochondrial Function	10%
Connectomics	10%
Autonomics	5%
Cervical–Vestibular Function	5%
Sensorimotor Function	3%
Cognitive/Psychiatric Function	2%

Score	Classification
<20	Stable / compensated
20–40	Mild Traumatic Connectomic Dysfunction
40–60	Moderate Neurotraumatic Collapse
60–80	Severe Traumatic Encephalopathy
>80	Critical Neurotraumatic Connectomic Failure

XVII. PRIMARY FDA-ALIGNED CLINICAL ENDPOINTS

Diagnostic-support endpoints

Glasgow Coma Scale
CT/MRI/SWI/DTI
GFAP + UCH-L1 in FDA-cleared TBI context
EEG when seizure or altered consciousness is suspected
Neurologic examination

Predictive endpoints

NfL
GFAP
DTI fractional anisotropy
qEEG slowing/connectivity
HRV SDNN/RMSSD
VOMS/cervical function testing

Therapeutic response endpoints

Reduced GFAP/NfL trend
Improved MoCA and processing speed
Improved HRV
Improved VOMS/balance/gait metrics
Improved Connectomic Collapse Index

NEXT PANEL IN SEQUENCE

SCF-ECCA-NEURODEG-BIO-0009

Neurodegenerative Encephalopathy Biomarker Panel

(Chronic Degenerative Connectomic Collapse Validation System)

MASTER REGISTRY INDEX

SCF-ECCA-TRA-BIO-0008 — Traumatic Encephalopathy Biomarker Panel
SCF-ECCA-TRA-ACU-0008 — Traumatic Encephalopathy Acupoint Neuro-Circuit Mapping Atlas
SCF-ECCA-0001 — Encephalopathy Connectomic Collapse Atlas
SCF-BIOMARKER-ENDPOINTS-0001 — SCF Biomarker Endpoint Validation Framework
SCF-PATH-PROT-0001 — SCF Pathophysiology Protocol
SCF-ACU-NEURO-ATLAS-0001 — SCF Neural Mapping Schema